MetroWest495 Biz

6 MetroWest495 Biz | May 2015 Phaneuf. For the last couple of years, BioSurfaces has utilized free counsel- ing services from the Massachusetts Small Business Development Center (MSBDC) at Clark University, the statement said. The MSBDC assisted BioSurfaces in strategic planning, ob- taining bank financing, and preparing a business plan for the company's spin- off, NuVascular Technologies. RXi gets orphan designation for melanoma drug A drug being developed by RXi Pharmaceuticals of Marlborough to treat patients with malignant melano- ma has secured "orphan" status from the federal government, allowing RXi to seek more incentives to bring it to market, the company announced. The drug, Samcyprone, is being developed to help prevent the skin-level spread of melanoma. The designation from the U.S. Food and Drug Administration qualified RXi for several incentives, including seven years of market ex- clusivity after the drug's approval, tax credits for clinical research costs and reductions in application fees, RXi said in a statement. The orphan designa- tion is reserved for drugs that are used to treat rare diseases or conditions and whose development costs might not be adequately recovered through sales. HART CEO steps down; search for replacement underway The CEO at biotech Harvard Ap- paratus Regenerative Technology (HART) of Holliston has resigned, replaced on an interim basis by CFO Thomas McNaughton, the company announced. HART is developing regenerated organs for transplant that are initially focused on the trachea, said David Green, who was CEO, president and board chairman, has stepped aside, although he'll remain on the board. John F. Kennedy, a member of the board since December 2012, has been named board chairman, the com- pany said. HART said it has begun a search for a new president and CEO. Boston Scientific finds new opportunity in China Boston Scientific has aligned itself with a Chinese company that will help the Marlborough-based medi- cal device manufacturer reach out to more doctors who remove stones from patients' bile ducts. Boston Scientific (BSX) will also buy an undisclosed stake in the company, Frankenman Medical Equipment Co., according to a statement from BSX. The agree- ment between the will allow both firms to reach more doctors and treat more patients by providing training on less-invasive endoscopic technologies, as well as their clinical and economic benefits, the BSX statement said. Warren Wang with BSX in China, said more than a million bile duct stone-re- moval procedures are performed each year in China. "While less invasive en- doscopic procedures can lead to better patient outcomes and reduced … costs, access to these procedures is extremely limited," he said in the statement. Corero Virginia partnership to boost attack protection Internet security provider Corero Network Security of Hudson is partner- ing with a Reston, Va., firm to improve customer defenses against distributed denial-of-service (DDoS) attacks. DDoS attacks seek to overwhelm online services with too much web traffic. A statement from Corero says the integrated approach combines Corero's on-premises technology with Verisign's cloud-based DDoS protection technol - ogy, OpenHybrid, to stop some DDoS attacks. Together, the architecture is designed to detect and respond to a large spectrum of DDoS attacks. Distribution deal for Natick's Convergent Dental Convergent Dental of Natick, a privately held dental equipment and technology company, has entered into a distribution partnership for its dental laser product, Solea. Dental practi- tioners will be able to buy Solea from Darby Dental Supply, the nation's largest all-telesales distributor of den- tal merchandise, Convergent Dental announced. Solea is a computer-aided micron laser used on hard and soft tis- sues. The product has been approved by the U.S. Food and Drug Admin- istration. Last month, Convergent announced it had secured $9 million in additional capital to help bring the product to market. Good scores for Arch Therapeutics' product Framingham-based medical de- vice maker Arch Therapeutics said a third-party, pre-clinical study rendered favorable data for its surgical product, AC5 Surgical Hemostatic Device. The study compared AC5's effectiveness in controlling wound bleeding with the effectiveness of a branded, commercially available fibrin sealant. The AC5 device, designed to control bleeding and fluid loss during surgical procedures, contains a self-assembling peptide comprised of naturally occurring amino acids that are not sourced from humans or animals. The statement from Arch said that gives AC5 an advantage over commercially available fibrin sealants that use hu - man blood products that are subject to contamination, and that require freezing and multistep preparation. Virtusa wrapping up acquisition Business consulting and technol- ogy outsourcing company Virtusa Corp. of Westborough has acquired all the outstanding shares of Appa- ratus Inc. for $34.2 million cash. The Indianapolis-based company provides end-to-end IT infrastructure services. The acquisition strengthens Virtusa's growing Infrastructure Management Services (IMS) practice with the ad- dition of Apparatus' Kore Managed Roundup s page 5 905 Hartford Turnpike, Shrewsbury, MA 01545 tel. 508.842.1213 • www.elevationee.com Before After Before After CUSTOM RENTAL GLOBAL GRAPHICS EVENTS PORTABLES UPGRADE YOUR SPACE • CORPORATE OFFICE DESIGN & INSTALL SIXTH ANNUAL FRIDAY, JUNE 5, 2015 8:30 am – 4:15 pm DCU Center Worcester, MA PRESENTED BY SPONSORED BY SUPPORTING SPONSORS COST: $150 | Register Online | WorcesterWomenLeadership.com • KEYNOTE SPEAKERS • BREAKOUT SESSIONS Laurie Forster The Standup Sommelier™ SPONSORED BY Kelly Swanson Storyteller, Comedian, Author SPONSORED BY • COMIC RELIEF • MARKETPLACE • BOOK SIGNINGS • NETWORKING #WWLC2015 FEATURES Lisa Ling Award-winning journalist, author, and host of CNN's 'This is Life' SPONSORED BY FEATURING

• Cover